Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

LCZ696

Catalog No: tcsc3409

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
936623-90-4

Formula:
$C_{48}H_{60}N_6Na_3O_{10}\cdot 5$

Pathway:
Metabolic Enzyme/Protease;GPCR/G Protein

Target:
Neprilysin;Angiotensin Receptor

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (104.39 mM); H2O : ≥ 50 mg/mL (52.19 mM)

Alternative Names:
Sacubitril mixture with Valsartan

Observed Molecular Weight:
957.99

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

LCZ696 is a dual **angiotensin II** receptor and **neprilysin** inhibitor.

In Vitro: LCZ696 is a single molecule that is comprised of molecular moieties of valsartan, an ARB, and AHU377, a neprilysin inhibitor (1:1 ratio)[1].

In Vivo: LCZ696 exerts a blood pressure lowering effect. Blood pressure reduction by LCZ696 is associated with a significant increase in urinary sodium excretion and sympathetic activity suppression. LCZ696 significantly ameliorates cardiac hypertrophy and inflammation, coronary arterial remodeling, and vascular endothelial dysfunction in high-salt loaded SHRcp compared with valsartan [1]. The neprilysin inhibitor component of LCZ696, LBQ657, inhibits hypertrophy but not fibrosis. The angiotensin receptor blocker component of LCZ696, valsartan inhibits both hypertrophy and fibrosis. Dual valsartan+LBQ augment the inhibitory effects of valsartan and the highest doses completely abrogate angiotensin II-mediated effects[2]. Pre-treatment with LCZ696 reduces the ischemic area. The decrease in cerebral blood flow in the peripheral region of the ischemic area is significantly attenuated by pre-treatment with LCZ696. LCZ696 pre-treatment significantly decreases the increase of superoxide anion production in the cortex on the ischemic side[3].